share_log

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-THE GOLDMAN SACHS GROUP, INC.(1.1 %),GOLDMAN SACHS & CO. LLC(1.1 %)

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-THE GOLDMAN SACHS GROUP, INC.(1.1 %),GOLDMAN SACHS & CO. LLC(1.1 %)

bluebird bio | SC 13G/A：超過5%持股股東披露文件(修正)-THE GOLDMAN SACHS GROUP, INC.(1.1 %),GOLDMAN SACHS & CO. LLC(1.1 %)
美股SEC公告 ·  2024/11/13 06:08

牛牛AI助理已提取核心訊息

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G with the United States Securities and Exchange Commission on November 7, 2024, indicating a change in their holdings of bluebird bio, Inc. The filing reveals that Goldman Sachs collectively has shared voting and dispositive power over 2,193,979 shares of bluebird bio, representing a 0.1% stake in the company. The document specifies that the shares are beneficially owned by certain operating units of Goldman Sachs and that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of bluebird bio. The filing includes various exhibits such as a joint filing agreement and powers of attorney, and it clarifies the organizational structure and authority within Goldman Sachs regarding the securities ownership.
Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G with the United States Securities and Exchange Commission on November 7, 2024, indicating a change in their holdings of bluebird bio, Inc. The filing reveals that Goldman Sachs collectively has shared voting and dispositive power over 2,193,979 shares of bluebird bio, representing a 0.1% stake in the company. The document specifies that the shares are beneficially owned by certain operating units of Goldman Sachs and that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of bluebird bio. The filing includes various exhibits such as a joint filing agreement and powers of attorney, and it clarifies the organizational structure and authority within Goldman Sachs regarding the securities ownership.
高盛集團及其子公司高盛有限責任公司已於2024年11月7日向美國證券交易委員會提交了修訂後的13G表，表明他們持有bluebird bio股份發生了變化。該文件顯示，高盛集體共享對bluebird bio的2,193,979股的投票權和處分權，這相當於公司的0.1%股權。文件明確指出，這些股份由高盛的某些運營單位有利益所有，這些證券是在正常業務活動中取得的，並非出於改變或影響bluebird bio控制權的目的。該文件包括各種展示文件，如聯合申報協議和授權委託書，並澄清了高盛內部有關證券所有權的組織架構和權威。
高盛集團及其子公司高盛有限責任公司已於2024年11月7日向美國證券交易委員會提交了修訂後的13G表，表明他們持有bluebird bio股份發生了變化。該文件顯示，高盛集體共享對bluebird bio的2,193,979股的投票權和處分權，這相當於公司的0.1%股權。文件明確指出，這些股份由高盛的某些運營單位有利益所有，這些證券是在正常業務活動中取得的，並非出於改變或影響bluebird bio控制權的目的。該文件包括各種展示文件，如聯合申報協議和授權委託書，並澄清了高盛內部有關證券所有權的組織架構和權威。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間